Skip to main content
SpringerLink
Log in

Physiological Changes Due to Age

Implications for the Prevention and Treatment of Thrombosis in Older Patients

  • Review Article
  • Physiological Aspects of Aging
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The risk of venous thromboembolism increases with age. This increasing risk is associated with a concurrent enhancement of coagulation activation and gradual development of a ‘prethrombotic state’. This is reflected by increased levels of coagulation activation peptides in the elderly, as well as decreased activity of the fibrinolytic system. Moreover, with increasing age there is an increased incidence of comorbid conditions, which may, in themselves, be associated with an increased risk for the development of thrombosis.

Accurate diagnostic techniques and strategies for treatment and prevention of deep vein thrombosis (DVT) are mandatory in order to prevent potentially fatal complications of DVT, such as pulmonary embolism. The feasibility of validated diagnostic techniques for detecting DVT, such as real-time B-mode ultrasonography, impedance plethysmography and contrast venography, is not significantly hampered in elderly patients. The same applies to strategies for prophylaxis and treatment of DVT, which are similar to those for younger patients, although formal studies in elderly patients with DVT are lacking.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hirsh J. Pulmonary embolism in the elderly. Cardiol Clin 1991; 9: 457–74

    PubMed  CAS  Google Scholar 

  2. Matzdorff AC, Green D. Deep vein thrombosis and pulmonary embolism: prevention, diagnosis and treatment. Geriatrics 1992; 47: 48–63

    PubMed  CAS  Google Scholar 

  3. Sevitt S, Gallagher NG. Venous thrombosis and pulmonary embolism: a clinico-pathological study in injured and burned patients. Br J Surg 1961; 48: 475–89

    PubMed  CAS  Google Scholar 

  4. Kakkar VV, Howe CT, Nicolaides AN, et al. Deep vein thrombosis of the leg: is there a high risk group? Am J Surg 1970; 120: 527–30

    PubMed  CAS  Google Scholar 

  5. Nicolaides AN, Irving D. Clinical risk factors and the risk of deep venous thrombosis. In: Nicolaides AN, editor. Thromboembolism: aetiology, advances in prevention and management. Lancaster: MTP Press, 1975: 193–204

    Google Scholar 

  6. Raskob GE, Hull RD. Venous thrombosis. In: Kwaan HC, Samama MM, editors. Clinical thrombosis. Boca Raton, Florida: CRC Press Inc, 1989: 59–89

    Google Scholar 

  7. Smith T, Viverette F, Adelman B. The use of antithrombotic therapy in the elderly. Clin Geriatr Med 1985; 1: 887–97

    PubMed  CAS  Google Scholar 

  8. Rosenberg RD. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, et al., editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott, 1987: 1373–92

    Google Scholar 

  9. Dahlbäck B. Protein S and C4-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66: 49–61

    PubMed  Google Scholar 

  10. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004–8

    PubMed  Google Scholar 

  11. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503–6

    PubMed  CAS  Google Scholar 

  12. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77–89

    PubMed  CAS  Google Scholar 

  13. Bachmann F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijnen HR, et al., editors. Thrombosis and haemostasis. Leuven: Leuven University Press, 1987: 227–65

    Google Scholar 

  14. Van Mourik JA, Lawrence DA, Loskuttof DJ. Purification of a Plasminogen activator (aniactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914–21

    PubMed  Google Scholar 

  15. Heeb MJ, Espana F, Geiger M, et al. Immunological identity of heparin dependent plasma and urinary protein C inhibitor and Plasminogen activator inhibitor-3. J Biol Chem 1987; 262: 15813–6

    PubMed  CAS  Google Scholar 

  16. Tracy R, Bovill E, Fried L, et al. The distribution of coagulation factors VII, VIII and fibrinogen in adults over the age of 65 years: results from the Cardiovascular Health Study. Ann Epidemiol 1992; 2: 509–19

    PubMed  CAS  Google Scholar 

  17. Balleisen L, Bailey J, Epping PH, et al. Epidemiological study on factor VII, factor VIII, and fibrinogen in an industrial population, I: baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill using, and menopause. Thromb Haemost 1985; 54: 475–9

    PubMed  CAS  Google Scholar 

  18. Bauer KA, Weiss LM, Sparrow D, et al. Aging-associated changes in indices of thrombin generation and protein C activation in humans: normative aging studies. J Clin Invest 1987; 80: 1527–34

    PubMed  CAS  Google Scholar 

  19. Kario K, Matsuo T, Kobayashi H. Which factors affect high D-dimer levels in the elderly. Thromb Res 1991; 62: 501–8

    PubMed  CAS  Google Scholar 

  20. Cadroy Y, Pierrejean D, Fontan B, et al. Influence of aging on the activity of the hemostatic system: Prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. Nouv Rev Fr Hematol 1992; 34: 43–6

    PubMed  CAS  Google Scholar 

  21. Rånby M, Bergsdorf N, Nilsson T, et al. Age dependence of tissue Plasminogen activator concentrations, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160–5

    PubMed  Google Scholar 

  22. Robertson BR, Pandolfi M, Nilsson IM. ‘Fibrinolytic capacity’ in healthy volunteers at different ages as studied by standardized venous occlusions of arms and legs. Acta Med Scand 1972; 191: 199–202

    PubMed  CAS  Google Scholar 

  23. Haeger K. Problems of acute deep venous thrombosis. I. The interpretations of signs and symptoms. Angiology 1969; 20: 219–23

    PubMed  CAS  Google Scholar 

  24. Wheeler HB. Diagnosis of deep vein thrombosis. Review of clinical evaluation and impedance plethysmography. Am J Surg 1985; 150(4A): 7–13

    PubMed  CAS  Google Scholar 

  25. Cranley JJ, Canos AJ, Sull WJ. The diagnosis of deep vein thrombosis. Fallibility of clinical signs and symptoms. Arch Surg 1976; 111: 34–6

    PubMed  CAS  Google Scholar 

  26. Cranley JJ, Canos AJ, Sull WJ. The diagnosis of deep venous thrombosis. Fallibility of clinical symptoms and signs. Arch Surg 1976; 111:34–6

    PubMed  CAS  Google Scholar 

  27. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134–44

    PubMed  CAS  Google Scholar 

  28. Lensing AWA, Büller HR, Prandoni, et al. Contrast venography, the gold standard for the diagnosis of deep vein thrombosis: improvement in observer agreement. Thromb Haemost 1992; 67: 8–12

    PubMed  CAS  Google Scholar 

  29. Bettmann MA, Paulin S. Leg phlebography: the incidence, nature and modification of undesirable side effects. Radiology 1977; 122: 101–4

    PubMed  CAS  Google Scholar 

  30. McLachan MSF, Thomson JG, Taylor DW, et al. Observer variation in the interpretation of lower limb venograms. Am J Radiol 1979; 132: 227–30

    Google Scholar 

  31. Lensing AWA, Prandoni P, Brandjes D, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989; 320: 342–5

    PubMed  CAS  Google Scholar 

  32. White RH, McGahan JP, Dasenbach MM, et al. Diagnosis of deep vein thrombosis using duplex ultrasound. Ann Intern Med 1989; 111:297–304

    PubMed  CAS  Google Scholar 

  33. Hull R, van Aken WG, Hirsh J, et al. Impedance plethysmography in the diagnosis of arterial and venous disease. Circulation 1976; 53: 696–700

    PubMed  CAS  Google Scholar 

  34. Kakkar VV. The diagnosis of deep vein thrombosis using the 125I-fibrinogen test. Arch Surg 1972; 104: 152–9

    PubMed  CAS  Google Scholar 

  35. Huisman MV, Büller HR, ten Cate JW, et al. Serial impedance plethysmography for suspected deep vein thrombosis in outpatients. The Amersterdam general practitioner study. N Engl J Med 1986; 314: 823–8

    PubMed  CAS  Google Scholar 

  36. Büller HR, Lensing AWA, Hirsh J, et al. Deep vein thrombosis: new non-invasive diagnostic tests. Thromb Haemost 1991; 66: 133–7

    PubMed  Google Scholar 

  37. Heijboer H, Büller HR, Lensing AWA, et al. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein-thrombosis in symptomatic outpatients. N Engl J Med 1993; 329: 1365–9

    PubMed  CAS  Google Scholar 

  38. Carter C, Gent M, Leclerc JR. The epidemiology of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, et al, editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott, 1987: 1185–98

    Google Scholar 

  39. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162–73

    PubMed  CAS  Google Scholar 

  40. Nurmohamed MT, Rosendaal FR, Büller HR, et al. The efficacy and safety of low molecular weight heparin versus standard heparin in general and orthopedic surgery: a meta-analysis. Lancet 1992; 340: 152–6

    PubMed  CAS  Google Scholar 

  41. Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in the prevention of perioperative thrombosis. BMJ 1992; 305: 913–20

    PubMed  CAS  Google Scholar 

  42. Jørgensen LN, Wille-Jørgensen, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993; 80: 689–704

    PubMed  Google Scholar 

  43. Nurmohamed MT, Büller HR, ten Cate JW. Prevention of venous thromboembolism in hip fracture patients. In: Marti RK, Dunki Jacobs PB, editors. Hip fractures, state of the art. London: Medical Press Ltd, 1993: 57–69

    Google Scholar 

  44. Salzman EW. Heparin for prophylaxis of venous thromboembolism. Ann NY Acad Sci 1989; 556: 371–7

    PubMed  CAS  Google Scholar 

  45. Sabri S, Roberts VC, Cotton LT. Prevention of early post-operative deep vein thrombosis by intermittent compression of the leg during surgery. BMJ 1971; 4: 394–6

    PubMed  CAS  Google Scholar 

  46. Scurr JH, Ibrahim SZ, Faber RG, et al. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis. Br J Surg 1977; 64: 371–3

    PubMed  CAS  Google Scholar 

  47. Skillman JJ, Collins REC, Coe NP, et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled randomized trial of external pneumatic compression boots. Surgery 1978; 83: 354–8

    PubMed  CAS  Google Scholar 

  48. Clarke-Pearson DL, Synan IS, Hinshaw WM, et al. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984; 63: 92–8

    PubMed  CAS  Google Scholar 

  49. Turpie AGG, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis in potential neurosurgical patients. Arch Intern Med 1989; 149:679–81

    PubMed  CAS  Google Scholar 

  50. Rasmussen A, Hansen PT, Lindholt J, et al. Venous thrombosis after abdominal surgery. A comparison between subcutaneous heparin and antithrombotic stockings, or both. J Med 1988; 19(3&4): 193–201

    PubMed  CAS  Google Scholar 

  51. Hartman JT, Pugh JL, Smith RD, et al. Cyclic sequential compression of the lower limb in prevention of deep venous thrombosis. J Bone Joint Surg 1982; 62: 1059–62

    Google Scholar 

  52. Gallus AS. Overview of the management of thrombotic disorders. Semin Thromb Hemost 1989; 15: 99–110

    PubMed  CAS  Google Scholar 

  53. Ljungström KG. The antithrombotic efficacy of dextran. Acta Chir Scand 1988; 543 (Suppl.): 26–30

    Google Scholar 

  54. Bronge A, Dahlgren S, Lindquist B. Prophylaxis against thrombosis in femoral neck fractures-a comparison between dextran 70 and dicumarol. Acta Chir Scand 1971; 137: 29–35

    PubMed  CAS  Google Scholar 

  55. Bergqvist D, Efsing HO, Hallböök T, et al. Thromboembolism after elective and post-traumatic hip surgery-A controlled prophylactic trial with dextran 70 and low-dose heparin. Acta Chir Scand 1979; 145:213–8

    PubMed  CAS  Google Scholar 

  56. Bergqvist E, Bergqvist D, Bronge A, et al. An evaluation of early thrombosis prophylaxis following fracture of the femoral neck. Acta Chir Scand 1972; 138: 689–93

    PubMed  Google Scholar 

  57. Bergqvist D, Efsing HO, Halböök T, et al. Prevention of postoperative thromboembolic complications. Acta Chir Scand 1980; 146: 559–68

    PubMed  CAS  Google Scholar 

  58. Raskob GE, Hull RD. Practical approaches for preventing venous thromboembolism. In: Kwaan HC, Samama MM, editors. Clinical thrombosis. Boca Raton, Florida: CRC Press Inc, 1989: 92–106

    Google Scholar 

  59. Morris GK, Mitchell JRA. Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. BMJ 1977; 1: 1535–7

    Google Scholar 

  60. Snook GE, Chrisman OD, Wilson TC. Thromboembolism after surgical treatment of hip fractures. Clin Orthop 1981; 155: 21–4

    PubMed  Google Scholar 

  61. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989; 149: 771–4

    PubMed  CAS  Google Scholar 

  62. Morris GK, Mitchell JRA. Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. Lancet 1976; 2: 869–72

    PubMed  CAS  Google Scholar 

  63. Borgstrom S, Greitz, van der Linden W, et al. Anticoagulant prophylaxis of venous thrombosis in patients with fractured neck of the femur. Acta Chir Scand 1965; 129: 500–8

    Google Scholar 

  64. Salzman EW, Davies GC. Prophylaxis of venous thromboembolism. Ann Surg 1980; 191: 207–18

    PubMed  CAS  Google Scholar 

  65. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988; 208: 227–46

    PubMed  CAS  Google Scholar 

  66. Xabregas A, Gray L, Ham JM. Heparin prophylaxis of deep vein thrombosis in patients with a fractured neck of the femur. Med J Aust 1978; 1: 620–2

    PubMed  CAS  Google Scholar 

  67. Lahnborg G. Effect of low-dose heparin and dihydroergotamine on frequency of postoperative deep-vein thrombosis in patients undergoing posttraumatic hip surgery. Acta Chir Scand 1980; 146: 319–22

    PubMed  CAS  Google Scholar 

  68. Svend-Hansen H, Bremerskov V, Gotrik J, et al. Low-dose heparin in proximal femoral fractures. Failure to prevent deep-vein thrombosis. Acta Orthop Scand 1981; 52: 77–80

    PubMed  CAS  Google Scholar 

  69. Moskovitz PA, Ellenberg SS, Feffer HL, et al. Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg 1978; 60A: 1065–70

    Google Scholar 

  70. Gallus AS, Hirsh J, Tuttle RJ, et al. Small subcutaneous dosis of heparin in prevention of venous thrombosis. N Engl J Med 1973; 288: 545–51

    PubMed  CAS  Google Scholar 

  71. Galasko CSB, Edwards DH, Fearn CBD’A, et al. The value of low dose heparin for the prophylaxis of thromboembolism in patients with transcervical and intertrochanteric femoral fractures. Acta Orthop Scand 1976; 47: 276–82

    PubMed  CAS  Google Scholar 

  72. Andersson LO, Barrowcliffe TW, Holmer E, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrixbound antithrombin HI and by gel filtration. Thromb Res 1976; 9: 975–83

    Google Scholar 

  73. Messmore HL, Griffin Jr B, Fareed J, et al. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann NY Acad Sci 1989; 556: 217–33

    PubMed  CAS  Google Scholar 

  74. ten Cate H, Henny ChP, ten Cate JW, et al. Use of a low molecular weight heparinoid in volunteers and hemodialysis patients. Thromb Res 1985; 38: 211–2

    Google Scholar 

  75. Carter CJ, Kelton JG, Hirsh J, et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239–45

    PubMed  CAS  Google Scholar 

  76. Ockelford PA, Carter CJ, Cerskus A, et al. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin III affinity heparin fraction. Thromb Res 1982; 27: 679–90

    PubMed  CAS  Google Scholar 

  77. Korninger C, Schlag G, Poigenfurst J, et al. Randomized trial of low molecular weight heparin (LMWH) versus low dose heparin/acenocoumarin (H/AC) in patients with hip fracture-Thromboprophylactic effect and bleeding complications [abstract]. Thromb Haemost 1989; 62: 187

    Google Scholar 

  78. Lassen, MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in hip fracture patients. Arch Orthop Trauma Surg 1989; 108: 10–3

    PubMed  CAS  Google Scholar 

  79. Gerhart TN, Yett HS, Robertson LK, et al. Low molecular weight heparinoid compared with warfarin for prophylaxis of deep vein thrombosis in patients who are operated on for fracture of the hip: a prospective randomized trial. J Bone Joint Surg 1991; 73A: 494–502

    Google Scholar 

  80. Bergqvist D, Kettunen K, Fredin H, et al. Thromboprophylaxis in patients with hip fracture: a prospective, randomized, comparative study between ORG 10172 and Dextran 70. Surgery 1991; 109: 617–22

    PubMed  CAS  Google Scholar 

  81. Pini M, Tabliaferri A, Manotti C, et al. Low molecular weight heparin (alfa LHWH) compared with unfractionated heparin in prevention of deep vein thrombosis after hip fractures. Int Angiol 1989; 8: 134–9

    PubMed  CAS  Google Scholar 

  82. Hoffmann R, Kohler A, Platz, et al. Prevention of deep vein thrombosis (DVT) in hip surgery: low molecular weight heparin (Sandoparin) versus 3 × 5000 LU. UF-heparin. A randomized prospective study [abstract]. Thromb Haemost 1993; 69: 1055

    Google Scholar 

  83. Powers P, Gent M, Klimek, et al. A randomized, double blind trial comparing a low molecular weight heparinoid, Orgaran, with aspirin in the prevention of venous thromboembolism following surgery for hip fracture [abstract]. Thromb Haemost 1993; 69: 1116

    Google Scholar 

  84. Stiekema JCJ, Wijnand HP, van Dinther ThG, et al. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol 1989; 27: 39–48

    PubMed  CAS  Google Scholar 

  85. Simoneau G, Bergmann JF, Kher A, et al. Pharmocokinetics of a low molecular weight heparin (Fragmin) in young and elderly subjects. Thromb Res 1992; 66: 603–7

    PubMed  CAS  Google Scholar 

  86. Hirudins: return of the leech [editorial]. Lancet 1992; 340: 579–80

  87. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16: 159–64

    PubMed  CAS  Google Scholar 

  88. Mottier D. Prophylaxis of deep venous thrombosis in medical geriatric patients [abstract]. Thromb Haemost 1993; 69: 1115

    Google Scholar 

  89. Brandjes DPM, Heijboer H, Büller HR, et al. A randomized double-blind clinical trial of acenocoumarol combined with heparin versus acenocoumarol alone in the initial treatment of proximalvein thrombosis. N Engl J Med 1992; 327: 1485–9

    PubMed  CAS  Google Scholar 

  90. Hirsh J, Marder VJ, Salzman EW, et al. Treatment of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ, et al., editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott, 1987: 1266–72

    Google Scholar 

  91. Gallus A, Jackamon J, Tillet J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 2: 1293–6

    PubMed  CAS  Google Scholar 

  92. Hull RD, Raskob GE, Hirsh J, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximalvein thrombosis. N Engl J Med 1990; 322: 1260–6

    PubMed  CAS  Google Scholar 

  93. Gallkus AS. Overview of the management of thrombotic disorders. Sem Thromb Hemost 1989; 15: 99–110

    Google Scholar 

  94. Hommes DW, Bura A, Mazzolai, et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis. Ann Int Med 1992; 116: 279–84

    PubMed  CAS  Google Scholar 

  95. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565–74

    PubMed  CAS  Google Scholar 

  96. Jick H, Slone D, Borda IT, et al. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 1968; 279: 284–6

    PubMed  CAS  Google Scholar 

  97. Vieweg WVR, Piscatelli RL, Houser JJ, et al. Complications of intravenous heparin administration in elderly women. JAMA 1970; 213: 1303–6

    PubMed  CAS  Google Scholar 

  98. Levine MN, Hirsh J, Kelton JG. Hemorrhagic complications of antithrombotic therapy. In: Colman RW, Hirsh J, Marder VJ, et al., editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott, 1987: 873–85

    Google Scholar 

  99. Levine MN, Hirsh J, Landefield S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1992; 102 (Suppl.): 352–63

    Google Scholar 

  100. Van der Meer FJM, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993; 153: 1557–62

    PubMed  Google Scholar 

  101. Holm HA, Ly B, Handeland GF, et al. Subcutaneous heparin treatment of deep vein thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16 (Suppl.): 30–7

    PubMed  Google Scholar 

  102. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin. Circulation 1989; 80: 935–9

    PubMed  CAS  Google Scholar 

  103. Bratt G, Aberg W, Johansson M, et al. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin. Thromb Haemost 1990; 64: 506–12

    PubMed  CAS  Google Scholar 

  104. Duroux P, Ninet J, Bachet P, et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991; 65: 251–6

    Google Scholar 

  105. Prandoni P, Lensing AWA, Büller HR, et al. Comparison of subcutaneous low molecular weight heparin in the treatment of proximal vein thrombosis. Lancet 1992; 339: 441–5

    PubMed  CAS  Google Scholar 

  106. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfraction-ated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68: 14–8

    PubMed  CAS  Google Scholar 

  107. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975–82

    PubMed  CAS  Google Scholar 

  108. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment of proximal vein thrombosis. Arch Intern Med 1993; 153: 1541–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, F4-131, Academic Medical Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Michael T. Nurmohamed, Harry R. Büller & Jan W. ten Cate

Authors
  1. Michael T. Nurmohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harry R. Büller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan W. ten Cate
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nurmohamed, M.T., Büller, H.R. & ten Cate, J.W. Physiological Changes Due to Age. Drugs & Aging 5, 20–33 (1994). https://doi.org/10.2165/00002512-199405010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199405010-00003

Keywords

Search

Navigation